Epitinib succinate
Epitinib succinate (HMPL-813 succinate) is an orally bioavailable, brain-penetrant EGFR inhibitor used in cancer research. It is employed in both in vitro and in vivo studies to investigate its potential therapeutic effects against EGFR-driven malignancies, including those affecting the central nervous system.
Product Specifications
CAS Number
2252334-12-4
Product Name Alternative
EGFR, Epitinib succinate, Epitinib Succinate, HMPL 813 Succinate, HMPL813 Succinate, HMPL-813 succinate, HMPL-813 Succinate
Field of Research
Cardiovascular Research, Signal Transduction
Purity
97.43% (May vary between batches)
Solubility
DMSO:1 mg/mL (1.82 mM) ;10% DMSO+40% PEG300+5% Tween 80+45% Saline:1 mg/mL (1.82 mM)
Smiles
OC (=O) CCC (O) =O.CCN1CCN (CC1) C (=O) Nc1cc2c (Nc3cccc (c3) C#C) ncnc2cc1OC
Molecular Formula
C28H32N6O6
Molecular Weight
548.59
Storage Conditions
-20°C
Notes
For research use only.
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
